紫杉醇联合放疗对中晚期宫颈癌的近期临床疗效分析

目的探讨紫杉醇联合同期放疗对于中晚期宫颈癌的近期临床疗效及其安全性。方法将我院近三年收治的83例IIb-IIIb期宫颈癌患者随机分为联合放化疗组和单纯放疗组,联合放化疗组43例,给予紫杉醇联合同期放疗,单纯放疗组40例,治疗完成后比较两组患者的近期临床疗效,并根据肿瘤的病理分型和大体分型比较两组的疗效。结果联合放化疗组治疗结束时以及治疗结束后3个月有效率分别为81.4%和95.3%,分别明显高于单纯放疗组(P<0.05);按照肿瘤的病理特征和大体分型进行分层分析,联合放化疗组各型宫颈癌的有效率也分别明显高于单纯放疗组(P<0.05);同时,联合放化疗组治疗后1年的局部复发率显著低于单纯放疗组(P<0.05)。结论与单纯放疗相比,紫杉醇联合同步放疗对中晚期宫颈癌患者具有较好的临床疗效,且对于局部复发具有较好的抑制作用。

Analysis of Short-Term Efficacy of Paclitaxel with Concurrent Radiotherapy in the Treatment of Cervical Cancer

Objective To analyze short-term efficacy and safety of paclitaxel plus concurrent radiotherapy in treating cervical cancer.Methods 83 patients with cervical cancer were enrolled and divided into chemoradiotherapy group(43 cases) and radiotherapy group(40 cases).Patients in chemoradiotherapy group were treated by paclitaxel with radiotherapy,and patients in radiotherapy group were only treated by radiotherapy.After treatment,the short-term clinical effects were compared according to the pathological classification and macroscopic types.Results The effective rates of chemoradiotherapy group were 81.4% right after treatment and 95.3% at three months after treatment,which were both significantly higher than those of radiotherapy group(P<0.05).According to the pathological classification and macroscopic types,the clinical effective rates of chemoradiotherapy group were also obviously higher than those of radiotherapy group(P<0.05).Meanwhile,1-year local recurrence rate of chemoradiotherapy group was significantly lower than that of radiotherapy group(P<0.05).Conclusion Paclitaxel combined with concurrent radiotherapy was more effective than single radiotherapy for cervical cancer.It also could better inhibit the local recurrence of cervical cancer.